PRESS RELEASE published on 01/07/2026 at 08:00, 2 months 15 days ago THX Pharma annonce la nomination de Julien Veys au poste de Directeur général adjoint Nomination de Julien Veys en tant que Directeur général adjoint chez THX Pharma, société spécialisée dans les maladies neurologiques rares. Stratégie d'enregistrement et commercialisation internationale de médicaments Nomination Commercialisation Neurologiques Rares THX Pharma Julien Veys
PRESS RELEASE published on 01/07/2026 at 08:00, 2 months 15 days ago THX Pharma Announces the Appointment of Julien Veys as Deputy Chief Executive Officer THX Pharma appoints Julien Veys as Deputy CEO to drive new strategy focusing on regulatory approval and commercialization of medicines for rare neurological diseases Regulatory Approval Deputy CEO Neurological Diseases THX Pharma Julien Veys
BRIEF published on 11/13/2025 at 08:05, 4 months 9 days ago THX Pharma successfully completes its €7.8 million capital increase Investors Capital Increase New Actions Neurological Diseases THX Pharma
BRIEF published on 11/13/2025 at 08:05, 4 months 9 days ago THX Pharma réussit son augmentation de capital de 7,8 millions d'euros Augmentation De Capital Investisseurs Actions Nouvelles Maladies Neurologiques THX Pharma
PRESS RELEASE published on 11/13/2025 at 08:00, 4 months 9 days ago THX Pharma announces the strong success of its approximately EUR 8 million capital increase to support its continued development and strengthen its financial structure THX Pharma successfully raises €7.8 million through capital increase, issuing 4,356,804 new shares at €1.80 each. Existing shareholders show strong support. Subscription period ran from Oct 29 to Nov 7, 2025, for the fully funded roadmap Shareholders Capital Increase New Shares Subscription Period THX Pharma
PRESS RELEASE published on 11/13/2025 at 08:00, 4 months 9 days ago THX Pharma annonce le vif succès de son augmentation de capital d'environ 8M EUR pour poursuivre son développement et renforcer sa structure financière THX Pharma annonce une levée de fonds de 7,8 M€ par émission d'actions nouvelles avec maintien du DPS. Succès de l'opération et objectifs futurs clairement définis Actions Nouvelles Levée De Fonds Valeur Maladies Neurologiques Rares THX Pharma
BRIEF published on 11/07/2025 at 18:05, 4 months 14 days ago Theranexus: Publication of voting rights and shares as of October 31, 2025 Share Capital Voting Rights Biopharmaceutical Rare Diseases Theranexus
BRIEF published on 11/07/2025 at 18:05, 4 months 14 days ago Theranexus : Publication des droits de vote et actions au 31 octobre 2025 Droits De Vote Capital Social Biopharmaceutique Maladies Rares Theranexus
PRESS RELEASE published on 11/07/2025 at 18:00, 4 months 14 days ago Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital THX Pharma publie le nombre d'actions et de droits de vote au 31 octobre 2025. La société biopharmaceutique traite les maladies neurologiques rares et est cotée sur Euronext Growth à Paris Droits De Vote Capital Social Euronext Growth Maladies Neurologiques Rares THX Pharma
PRESS RELEASE published on 10/23/2025 at 08:00, 4 months 30 days ago THX Pharma annonce le lancement d'une augmentation de capital avec maintien du DPS d'un montant d'environ 8M EUR
Published on 03/20/2026 at 13:30, 2 days 4 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days 5 hours ago CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Published on 03/22/2026 at 12:23, 5 hours 21 minutes ago Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 1 day 18 hours ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 1 day 20 hours ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 1 day 20 hours ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 21:00, 1 day 20 hours ago BRP Unveils the Winners of its 6th International Design Challenge
Published on 03/20/2026 at 19:00, 1 day 22 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 1 day 22 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 1 day 23 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 1 day 23 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA